The Role of the Soluble CD30 Serum Level in Colorectal Cancer: A Possible Marker for a Patient Subset Which Could Benefit from IL-2 Biotherapy

Tiziana Del Beato, Anna Maria Berghella, Patrizia Pellegrini, Adorno Domenico, Carlo Umberto Casciani

Open source

DOI
10.1089/cbr.1997.12.297
Published
1997-10
Container
Cancer Biotherapy and Radiopharmaceuticals
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1089/cbr.1997.12.297,
  title = {The Role of the Soluble CD30 Serum Level in Colorectal Cancer: A Possible Marker for a Patient Subset Which Could Benefit from IL-2 Biotherapy},
  author = {Tiziana Del Beato and Anna Maria Berghella and Patrizia Pellegrini and Adorno Domenico and Carlo Umberto Casciani},
  year = {1997},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  doi = {10.1089/cbr.1997.12.297},
  url = {https://doi.org/10.1089/cbr.1997.12.297}
}

RIS

TY  - JOUR
TI  - The Role of the Soluble CD30 Serum Level in Colorectal Cancer: A Possible Marker for a Patient Subset Which Could Benefit from IL-2 Biotherapy
AU  - Tiziana Del Beato
AU  - Anna Maria Berghella
AU  - Patrizia Pellegrini
AU  - Adorno Domenico
AU  - Carlo Umberto Casciani
PY  - 1997
JO  - Cancer Biotherapy and Radiopharmaceuticals
DO  - 10.1089/cbr.1997.12.297
UR  - https://doi.org/10.1089/cbr.1997.12.297
ER  - 

APA

Beato, T. D., Berghella, A. M., Pellegrini, P., Domenico, A., & Casciani, C. U. (1997). The Role of the Soluble CD30 Serum Level in Colorectal Cancer: A Possible Marker for a Patient Subset Which Could Benefit from IL-2 Biotherapy. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.1997.12.297

Source records